1 / 25

ACE inhibitors and the Kidney

ACE inhibitors and the Kidney. William G. Paxton, MD, PhD Nephrology Medical Associates of GA. At what creatinine do you stop using an ACE inhibitor?. Let’s think about the physiology!. History of RAS. 1898 Tigerstedt “Renin” 1930’s Angiotonin/Hypertensin - “Angiotensin”

denim
Download Presentation

ACE inhibitors and the Kidney

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACE inhibitors and the Kidney William G. Paxton, MD, PhD Nephrology Medical Associates of GA

  2. At what creatinine do you stop using an ACE inhibitor?

  3. Let’s think about the physiology!

  4. History of RAS • 1898 Tigerstedt “Renin” • 1930’s Angiotonin/Hypertensin - “Angiotensin” • 1977 Captopril developed • 1991 AT1 Receptor Cloned • 1996 Losartan

  5. Angiotensinogen Renin Angiotensin I Bradykinin ACE ACEi Non ACE (-) (-) Angiotensin II Inactive Metabolites ARB AT2 Receptor AT1 Receptor

  6. Vasoconstriction • Aldosterone synthesis and release • Induces salt and water reabsorption • Mediates thirst, salt appetite • Secretion of vasopressin • Growth factor Angiotensin II (Ang II) Octapeptide hormone Asp - Arg - Val - Tyr - Ile - His - Pro - Phe Physiological effects

  7. Angiotensin II Binds to cell surface receptors Two receptor subtypes AT Expressed in mature tissues 1 Blocked by losartan (DuP 753) AT Expressed in fetal tissue 2 Blocked by PD 123177 AT receptor mediates all known physiological effects * 1

  8. The Kidney (AT1 Receptors) • Afferent and Efferent Arterioles • Mesangial Cells • Renal Medulla (esp. inner stripe of outer medulla) • Juxtaglomerular Cells

  9. ACEi in Hypertension • Relaxes vascular smooth muscle • Inhibits salt and water reabsorption (aldo) • Inhibits water seeking behavior

  10. Clinical Indications for ACEi • Hypertension • CHF • S/p MI • Diabetes Mellitus • Proteinuria • Vascular Disease • Post - transplant

  11. The Kidney • Decreases Proteinuria (DM and Non-DM) • Beneficial effect on permeability • Beneficial effect on size selectivity • Slow the Rate of GFR Decline

  12. The Heart - Organ • Prevents cardiac hypertrophy • Limits infarct size • Improves cardiac function • Improves cardiac metabolism

  13. The Heart Outcomes Prevention Evaluation Study (HOPE)

  14. HOPE • 9297 Patients • Age >55 • Vascular Disease/DM + 1 other CV factor • Normal EF (>40%) • Ramipril (10mg) vs. Placebo

  15. HOPE • MI • Stroke • Death (CV causes)

  16. HOPE (Primary endpoints) • Death (CV) - 6.1 vs 8.1 P<0.001 RR=0.75 • MI - 9.9 vs 12.2 P<0.001 RR=0.80 • Stroke - 3.4 vs 4.9 P<0.001 RR=0.69

  17. HOPE (secondary endpts.) • Death 10.4 vs 12.2 • Revascularization 16.0 vs 18.6 • Cardiac arrest 0.8 vs 1.2 • Heart Failure 7.4 vs 9.4 • DM complications 6.2 vs 7.4 * all statistically significant

  18. Summary • RAS has many effect on different tissues • ACEi and ARBs not equvalent • Many clinical indications for ACEi

  19. At what creatinine do you stop using an ACE inhibitor?

  20. Depends on the clinical situation!!

More Related